Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

PURPOSE: When during cancer treatment resistance to a tyrosine kinase inhibitor (TKI) occurs, switching to another TKI is often considered as a reasonable option. Previously, we reported that resistance to sunitinib may be caused by increased lysosomal sequestration, leading to increased intracellul...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cell Oncol (Dordr)
Main Authors: Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Format: Artigo
Sprog:Inglês
Udgivet: Springer Netherlands 2015
Fag:
Original Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4555235/
https://ncbi.nlm.nih.gov/pubmed/25665527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-015-0218-8
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker